Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab for refractory ulcerative colitis.

W Y Chey1, A Hussain, C Ryan

  • 1Konar Center for Digestive and Liver Diseases, Rochester, New York, USA.

The American Journal of Gastroenterology
|August 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for a Neutral Gauge Boson with Nonuniversal Fermion Couplings in Vector Boson Fusion Processes in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2025
Same author

First Measurement of ν_{e} and ν[over ¯]_{e} Charged-Current Single Charged-Pion Production Differential Cross Sections on Argon Using the MicroBooNE Detector.

Physical review letters·2025
Same author

Perineuronal net degradation causes a delayed change in resting and sound evoked responses in the mouse auditory cortex.

Neuroscience·2025
Same author

Reweighting simulated events using machine-learning techniques in the CMS experiment.

The European physical journal. C, Particles and fields·2025
Same author

The Multiple Dosing Effects of Platelet-Rich Plasma on Cartilage Regeneration in Knee Osteoarthritis: Randomised, Placebo-Controlled Trial.

Malaysian orthopaedic journal·2025
Same author

Search for Fractionally Charged Particles in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2025
Same journal

Calendar of Courses, Symposiums and Conferences.

The American journal of gastroenterology·2026
Same journal

Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

The American journal of gastroenterology·2026
Same journal

ACG Clinical Guideline: Colonic Diverticulitis.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

2026 CME Information.

The American journal of gastroenterology·2026
See all related articles

Chimeric monoclonal antibody infliximab (anti-TNF alpha) effectively induced remission in eight patients with severe ulcerative colitis (UC) refractory to standard treatments. This groundbreaking therapy showed significant clinical, endoscopic, and histological improvements with no adverse events observed.

Area of Science:

  • Gastroenterology and Immunology
  • Inflammatory Bowel Disease Research
  • Biologic Therapies

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Refractory UC cases often necessitate colectomy.
  • Current therapies have limitations for severe, treatment-resistant patients.

Observation:

  • Eight patients with active UC, unresponsive to standard therapies and candidates for surgery, were enrolled.
  • A single intravenous dose of infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor alpha, was administered.
  • Patients exhibited severe, active disease refractory to conventional treatments.

Findings:

  • All eight patients demonstrated a robust response to infliximab infusion.
  • Significant clinical, colonoscopic, and histological improvements were observed post-treatment.

Related Experiment Videos

  • No major complications or side effects were reported during the study.

    • Implications:

    • Infliximab is a potent therapeutic option for inducing remission in refractory UC patients.
    • This biologic agent offers a promising alternative to colectomy for severe UC.
    • Further research is warranted to determine the long-term remission duration and efficacy.